<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03751007</url>
  </required_header>
  <id_info>
    <org_study_id>AG019-T1D-101</org_study_id>
    <secondary_id>2017-002871-24</secondary_id>
    <nct_id>NCT03751007</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D)</brief_title>
  <official_title>A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Precigen Actobio T1D, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Intrexon Actobiotics NV, d/b/a Precigen Actobio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TFS Trial Form Support</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Precigen Actobio T1D, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of different doses of&#xD;
      AG019 administered alone or in combination with teplizumab in participants who recently&#xD;
      developed Type 1 Diabetes Mellitus (T1D).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1b/2a, multi-center study will be conducted in participants with clinical&#xD;
      recent-onset Type 1 Diabetes Mellitus (T1D).&#xD;
&#xD;
      The primary objective of this study is to assess the safety and tolerability of different&#xD;
      doses of AG019 alone as well as AG019 in association with teplizumab. The secondary&#xD;
      objectives of this study are: to obtain pharmacodynamic (PD) data of AG019 alone as well as&#xD;
      AG019 in association with teplizumab; and to determine the potential presence of AG019 in&#xD;
      systemic circulation (safety - systemic exposure) and the presence of L. lactis bacteria in&#xD;
      fecal excretion (local exposure): Pharmacokinetic (PK) profile.&#xD;
&#xD;
      This study consists of 2 phases:&#xD;
&#xD;
      Phase 1b: this open-label part of the study will investigate the safety and tolerability of 2&#xD;
      different doses of AG019 in 2 age groups (18-40 years of age and 12-17 years of age).&#xD;
&#xD;
      Phase 2a: this randomized, double-blind part of the study will investigate the safety and&#xD;
      tolerability of AG019, in association with teplizumab, in 2 age groups (18-40 years of age&#xD;
      and 12-17 years of age).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2018</start_date>
  <completion_date type="Actual">October 13, 2021</completion_date>
  <primary_completion_date type="Actual">October 13, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The Phase 1b part of the study will enroll 4 sequential AG019 cohorts of up to 6 Participants, in ascending dose cohorts and descending age cohorts. All participants in these cohorts will be treated with AG019 in an open label fashion.&#xD;
The Phase 2a part of the study will evaluate 2 cohorts of participants administered AG019 and teplizumab. The first 2 participants will be treated with active treatment in an open label fashion. Participants 3-12 will be randomized (4:1) to receive active treatment or placebo in a double-blind fashion.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>For the randomized participants in the combination cohorts, blinding will be accomplished by arranging for AG019 and placebo components as well as teplizumab and placebo components to have identical packaging.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events assessed by the investigator, review of lab reports and information provided by the participant during site visits and/or participant diary during treatment with AG019 alone or with teplizumab</measure>
    <time_frame>up to 6 months from screening</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune marker cell count in systemic circulation.</measure>
    <time_frame>Up to 12 months after initiation of the treatment</time_frame>
    <description>Immune markers will be measured in cells/mm^3 and may include: human proinsulin (hPINS), specific cluster of differentiation(CD)4+ T cells and circulating interleukin-10 (IL-10) producing CD4+ T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines/chemokines in systemic circulation.</measure>
    <time_frame>Up to 12 months after initiation of the treatment</time_frame>
    <description>Cytokines/chemokines will be measured in pg/mL and may include: interferon(IFN)-gamma, IL-10 and chemokine receptor type 6 (CCR6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AG019 in systemic circulation</measure>
    <time_frame>Up to 12 months after initiation of the treatment</time_frame>
    <description>The presence of live L. Lactis bacteria in blood will be assessed by plating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>L. Lactis-secreted hPINS or hIL-10 in systemic circulation</measure>
    <time_frame>Up to 12 months after initiation of the treatment</time_frame>
    <description>The presence of L. lactis-secreted hPINS or hIL-10 in the blood will be assessed by ELISA (enzyme-linked immunosorbent assay)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AG019 in feces</measure>
    <time_frame>Up to 12 months after initiation of the treatment</time_frame>
    <description>The presence of L. lactis (live or dead) in feces will be assessed by Q-PCR (quantitative real-time polymerase chain reaction)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-emergent adverse events as assessed by the investigator observed at timepoints other than those specified in the Primary Outcome.</measure>
    <time_frame>Up to 12 months from screening</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>AG019 Cohort 1 - Low Dose/Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AG019 Cohort 2 - High Dose/Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AG019 Cohort 3 - Low Dose/Adolescents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AG019 Cohort 4 - High Dose/Adolescents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Cohort 1 - Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Cohort 2 - Adolescents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AG019 - Low Dose</intervention_name>
    <description>Solid, orally administered capsule - 2 capsules per day for 1 day (single dose) or 8 weeks (repeat dose)</description>
    <arm_group_label>AG019 Cohort 1 - Low Dose/Adults</arm_group_label>
    <arm_group_label>AG019 Cohort 3 - Low Dose/Adolescents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teplizumab</intervention_name>
    <description>Daily IV infusions of Teplizumab during the first 12 days of AG019 treatment. Total cumulative dose is approximately 17mg (dose calculation based on body surface area).</description>
    <arm_group_label>Combination Cohort 1 - Adults</arm_group_label>
    <arm_group_label>Combination Cohort 2 - Adolescents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-AG019</intervention_name>
    <description>Formulated identically to AG019 with the active ingredient removed.</description>
    <arm_group_label>Combination Cohort 1 - Adults</arm_group_label>
    <arm_group_label>Combination Cohort 2 - Adolescents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-Teplizumab</intervention_name>
    <description>Formulated identically to teplizumab with the active ingredient removed.</description>
    <arm_group_label>Combination Cohort 1 - Adults</arm_group_label>
    <arm_group_label>Combination Cohort 2 - Adolescents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AG019 - High Dose</intervention_name>
    <description>Solid, orally administered capsule - 6 capsules per day for 1 day (single dose) or 8 weeks (repeat dose)</description>
    <arm_group_label>AG019 Cohort 2 - High Dose/Adults</arm_group_label>
    <arm_group_label>AG019 Cohort 4 - High Dose/Adolescents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AG019 - Low or High Dose</intervention_name>
    <description>Solid, orally administered capsule - 2 or 6 capsules per day for 8 weeks (repeat dose).</description>
    <arm_group_label>Combination Cohort 1 - Adults</arm_group_label>
    <arm_group_label>Combination Cohort 2 - Adolescents</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant, non-lactating females, 18 - 40 years of age (both inclusive) or&#xD;
             12-17 years of age (both inclusive)&#xD;
&#xD;
          -  Diagnosis of diabetes according to the American Diabetes Association (ADA) recommended&#xD;
             criteria&#xD;
&#xD;
          -  Evidence of auto-antibodies to at least 1 β-cell autoantigen&#xD;
&#xD;
          -  Stimulated C-peptide measured during 4h Mixed Meal tolerance Test (MMTT) &gt; 0.2 nmol/L&#xD;
&#xD;
          -  The first administration of AG019 should occur no later than 150 days post diagnosis&#xD;
             of diabetes&#xD;
&#xD;
          -  Body weight ≥ 33kg&#xD;
&#xD;
          -  Written informed consent obtained and documented (participant, parent, guardian as&#xD;
             applicable)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous history of serious cytokine release syndrome to teplizumab or other humanized&#xD;
             anti-CD3 monoclonal antibodies with no or minimal capacity to bind Fc receptors.&#xD;
             (Participants enrolled in the second phase of the trial in either Combination Cohort 1&#xD;
             or Combination Cohort 2, only)&#xD;
&#xD;
          -  Use of immunosuppressive or immunomodulatory therapies, including systemic steroids&#xD;
             within 1 month prior to randomization&#xD;
&#xD;
          -  Participation in another investigational drug trial within 12 weeks prior to the first&#xD;
             study drug intake and during participation in this study&#xD;
&#xD;
          -  History of recurrent infections, other autoimmune diseases, cardiac disease,&#xD;
             malignancy, or any other (chronic) medical condition which, in the investigator's&#xD;
             opinion, could compromise participant safety&#xD;
&#xD;
          -  Documented history of human immunodeficiency virus (HIV), Hepatitis Virus Type C&#xD;
             (HCV), Hepatitis Virus Type B (HBV) infection&#xD;
&#xD;
          -  Evidence of active infection with Epstein-Barr Virus (EBV) or cytomegalovirus (CMV)&#xD;
&#xD;
          -  Evidence of active or latent tuberculosis (TB)&#xD;
&#xD;
          -  Administration of anti-CD3 antibody in past year&#xD;
&#xD;
          -  Current therapy with any other anti-diabetic agents other than insulin (MDI, CSII or&#xD;
             analogue). Current or planned therapy with experimental (i.e., unapproved) insulin.&#xD;
             Patients on therapy for type 2 diabetes (e.g. metformin) should stop their therapy in&#xD;
             order to be eligible for study participation.&#xD;
&#xD;
          -  Use of medications known to influence glucose tolerance&#xD;
&#xD;
          -  Daily use of non-steroidal anti-inflammatory agents&#xD;
&#xD;
          -  Compromised GI mucosal integrity or motility, not attributable to T1D (i.e., recent&#xD;
             diarrhea, gluten sensitive enteropathy, inflammatory bowel disease, irritable bowel&#xD;
             syndrome), or current use of medications known to influence GI motility&#xD;
&#xD;
          -  Positive result of SARS-Cov2 PCR test at screening or within 3 days before&#xD;
             randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chantal Mathieu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Leuven, Clinical and Experimental Endocrinology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevan Herold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale Center for Clinical Investigation; Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Metabolic Research Centre</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Center for Clinical Investigation</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barry J Reiner, MD, LLC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Health</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri-Kansas City School of Medicine</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Children's Specialty Clinic</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Diabetes and Endocrine Consultants</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes &amp; Endocrinology, P.A.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78749</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2018</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

